GleamWall
中文EN

KPRX KIORA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1372514 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.9%
TTM net income YoY-529.2%
TTM EPS YoY84.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-55,210.8%
Net margin-60,257.3%
FCF margin—
EBITDA margin-55,137.5%

Returns

ROE-41.1%
ROA-31.5%
ROIC (approx.)-74.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio5.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-11.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.00M——$0$0$0$0$0
R&D expense$1.95M$2.08M$2.12M$2.93M$2.73M$2.59M$2.53M$4.12M
SG&A expense$1.58M$1.38M$1.61M$1.46M$1.44M$1.35M$1.49M$1.33M
Operating income-$1.69M-$2.21M-$2.51M-$7.31M-$794,437-$2.40M-$2.33M-$2.56M
Pretax income-$1.58M-$2.08M-$2.42M-$7.17M-$616,323-$2.26M-$2.07M-$2.16M
Income tax$165,000$0$0-$649,970-$643,129-$112,057$123,006$2.07M
Net income-$1.75M-$2.08M-$2.42M-$6.52M$26,806-$2.15M-$2.19M-$4.22M
EBITDA-$1.68M-$2.20M-$2.50M-$7.30M-$783,885-$2.39M-$2.33M-$2.56M
EPS (basic)-0.28-0.34-0.58—0.01-0.54-0.52—
EPS (diluted)-0.28-0.34-0.58—0.01-0.54-0.52—
Weighted avg. shares (diluted)6.30M6.18M4.17M—4.36M3.99M4.22M—
Balance sheet
Cash & equivalents$5.57M$7.08M$10.96M$8.70M$5.51M$1.03M$3.78M$3.80M
Short-term investments$10.72M$9.76M$2.92M$8.39M$13.87M$19.64M$20.33M$23.00M
Receivables$636,756$1.09M$1.54M$1.52M$1.21M$2.42M$1.34M$601,197
Current assets$19.91M$21.26M$18.68M$21.75M$22.69M$24.74M$27.11M$29.71M
PP&E, net$88,192$99,637$86,815$91,672$101,807$106,843$4,984$5,232
Intangibles$2.06M$2.06M$2.06M$2.06M$6.69M$6.69M$6.69M$6.69M
Total assets$22.37M$23.78M$21.23M$24.25M$29.86M$31.95M$34.02M$36.48M
Current liabilities$2.52M$2.37M$2.80M$3.63M$2.58M$3.19M$5.27M$6.01M
Total liabilities$7.08M$6.92M$7.29M$8.13M$7.45M$9.82M$10.32M$10.72M
Shareholders' equity$15.30M$16.86M$13.93M$16.13M$22.41M$22.13M$23.70M$25.76M
Shares outstanding4.42M4.43M3.99M3.76M3.43M3.43M3.00M3.00M
Cash flow statement
Operating cash flow-$557,518-$1.89M-$3.16M-$2.18M-$1.27M-$3.80M-$2.70M-$2.25M
Capital expenditure$355$23,456$5,018$78,163$431$32,195$0-$45,031
Free cash flow-$557,873-$1.92M-$3.17M-$2.26M-$1.27M-$3.84M-$2.70M-$2.21M
Investing cash flow-$958,330-$6.89M$5.40M$5.35M$5.74M$664,172$2.67M$482,683
Financing cash flow-$7,397$4.92M-$842$296$0$265,359$0$0
Depreciation & amortization$12,141$10,741$10,563$10,508$10,552$3,423$318$5,912
Stock-based compensation$186,196$109,310$209,510$234,448$254,398$262,774$148,616$160,180

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.